GEH 120714

Drug Profile

GEH 120714

Alternative Names: [18F] GEH120714; [18F]-GE180; flutriciclamide [18F]; GE 180; GEH120714

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Imaging agents; Radioisotopes
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis
  • No development reported Neurological disorders

Most Recent Events

  • 08 Mar 2017 CTP push 237990 (NCT01738347) - trial doesn't mention USA as trial site; removed USA from dev, added trial completion and ADS
  • 23 Feb 2017 GEH 120714 is still in phase I development for Multiple sclerosis (Diagnosis) in Canada (NCT01738347)
  • 01 May 2016 GE Healthcare completes a phase-I trial in Multiple sclerosis (Diagnosis) in Canada (IV) (NCT01738347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top